🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05615038
Active, not recruiting Not applicable

A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion

NCT05615038 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Started
2022-11-07
Last updated
2025-04-27

Condition(s) studied

Basilar Artery OcclusionEndovascular Treatment

Investigational drug(s) / intervention(s)

Contact aspiration ThrombectomyStent retriever thrombectomy

Contact aspiration Thrombectomy: Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.

Stent retriever thrombectomy: Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.

Study summary

Compare the effectiveness and safety of contact aspiration (CA) and stent retriever (SR) in acute ischemic stroke patients with basilar artery occlusion.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age≥18 years; 2. Acute basilar artery occlusion confirmed by CTA/MRA/DSA; 3. Last known well to puncture time≤24 hours; 4. pc-ASPECTS score≥6 points; 5. Baseline NIHSS score≥10 points; 6. Consent to endovascular treatment; 7. Informed consent signed. Clinical Exclusion Criteria: 1. Baseline mRS≥3 points; 2. Known or suspected severe basilar artery stenosis (\>70%) or chronic occlusion based on history, imaging, or clinical manifestations; 3. Refractory hypertension that is difficult to be controlled by drugs (defined as persistent systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg) 4. Genetic or acquired hemorrhagic tendency, coagulation factor deficiency or on anticoagulant therapy and International Normalized Ratio (INR) \> 3.0; 5. Laboratory tests: baseline blood glucose \<50mg/dl (2.8mmol/L) or \>400mg/dl (22.2mmol/L); Baseline platelet count \<50×109/L; 6. Known severe allergy (more severe than skin rash) to contrast agents uncontrolled by medications; 7. Females who are pregnant, or those of childbearing, potential with positive urine or serum beta Human Chorionic Gonadotropin test; 8. Other circumstances that the investigator considers inappropriate for participation in the trial or that may pose significant risks to patients (such as inability to understand and/or follow the study procedures and/or follow up due to mental disorders, cognitive or emotional disorders). Imaging Exclusion Criteria: 1. CT or MR evidence of acute intracranial hemorrhage (the presence of microbleeds on MRI is allowed); 2. Midline shift or herniation, mass effect with effacement of the ventricles; 3. Complete cerebellar infarct on CT or MRI with significant mass effect and compression of the 4-th ventricle; 4. Complete bilateral thalamic infarction on CT or MRI; 5. Inability to endovascular treatment due to Excessive tortuosity, variation, or dissection of the artery; 6. Subjects with occlusions in both intracranial vertebral arteries; 7. Subjects with occlusions in both anterior and posterior circulation; 8. Evidence of intracranial tumor (except small meningioma).

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
The First Affiliated Hospital of Anhui Medical University Hefei Anhui
Beijing Anzhen Hospital Beijing Beijing Municipality
Beijing Daxing District People's Hospital Beijing Beijing Municipality
Anyang People's Hospital Anyang Henan
Zhangzhou Municipal Hospital Zhangzhou Henan
Baotou Center Hospital Baotou Neimenggu

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05615038 on ClinicalTrials.gov ↗ ← All trials in China